Alexander disease, also known as primary astrocyte disease, is a neurological disorder caused by mutations in the astrocyte-specific gene GFAP. The most prominent pathological finding is Rosenthal fiber formation within the astrocyte cytoplasm, which is primarily composed of GFAP and heat shock proteins (α-B crystalline, HPS27). Although astrocyte-derived changes may have widespread effects on the central nervous system, resulting in pathological changes and clinical manifestations, the etiological mechanisms of the disease remain underexplored. Our recent study focused on microglia, a type of glial cell, and showed that microglia actively participate in the pathophysiology of Alexander disease. In a mouse model of Alexander disease, we observed that microglia sense elevated extracellular adenosine triphosphate (ATP) produced by astrocytic pathology as a pathological signal through the P2Y12 receptor and suppress astrocyte pathology. Microglia have been shown to have important disease-modifying effects on Alexander disease. Overall, this study will contribute to the development of microglial manipulation-based therapies. In this review, we discuss the clinical features and experimental research on Alexander disease conducted to date. In addition, we discuss the topics of our recent study.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.11477/mf.188160960770030281 | DOI Listing |
Front Immunol
March 2025
Department of Dermatology, Gesundheit Nord Klinikverbund Bremen, Bremen, Germany.
Background: Although systemic therapies have improved considerably over the last decade, up to 50% of patients with metastatic melanoma still die due to disease progression. Oncological treatment at the end-of-life phase is challenging. The aim of this study was to investigate the frequency and type of systemic therapy received by melanoma patients in their end-of-life phase.
View Article and Find Full Text PDFIntroduction: Richter's transformation (RT) from chronic lymphocytic leukemia (CLL) to lymphoma carries poor prognosis. This case series examines the efficacy of lisocabtagene maraleucel (liso-cel) in six RT patients, highlighting the impact of concurrent ibrutinib therapy.
Methods: Six patients were with RT who received liso-cel from were included in this single institution case series.
Cureus
February 2025
Department of Radiology, Juntendo University Graduate School of Medicine, Tokyo, JPN.
Background and aim The natural progression of liver fibrosis and its association with biomarker changes have not been fully established in the literature. This study aimed to investigate liver fibrosis progression in patients with hepatitis B virus (HBV) and hepatitis C virus (HCV) infection using a novel machine learning tool called 'Subtype and Stage Inference (SuStaIn).' SuStaIn can identify disease progression patterns and subgroups from cross-sectional biomarker data.
View Article and Find Full Text PDFEur J Nucl Med Mol Imaging
March 2025
Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany.
Purpose: Due to new advances in molecular and imaging biomarkers, a biological classification of Parkinson's disease (PD) called SyNeurGe (Hoglinger et al. Lancet Neurol 2024;23:191-204) has been proposed for research use recently. [I]ioflupane dopamine transporter single-photon-emission-computed tomography (DaT-SPECT) and cardiac [I]meta-iodobenzylguanidine (MIBG) scintigraphy are included in this biological classification scheme together with 2-[F]fluoro-2-deoxy-D-glucose (FDG-PET) as central imaging biomarkers for the assessment of dopaminergic function, cardiac sympathetic denervation, and metabolic patterns in brain.
View Article and Find Full Text PDFArthritis Rheumatol
March 2025
Department of Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, 40225, Düsseldorf, Germany.
Objectives: Systemic sclerosis (SSc) is a connective tissue disease with fibrotic remodeling of the skin and various internal organs. SSc is associated with the highest case-specific mortality of all rheumatic autoimmune diseases with limited antifibrotic treatment options. Here, we evaluated the therapeutic effects of the highly selective 5-hydroxytryptamine 2B receptor (5-HTR) inhibitor AM1476.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!